Systemic Sclerosis With and Without Interstitial Lung Disease
1 clinical trials · Condition
◉ Watch Systemic Sclerosis With and Without Interstitial Lung Disease
| Record | Firm | Date |
|---|---|---|
| A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) (NCT04948554) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2023-03-10 |
Track Systemic Sclerosis With and Without Interstitial Lung Disease automatically
Every clearance here is in the API, with alerts when new ones post.